Spots Global Cancer Trial Database for TCR Alpha/Beta and CD19-deplete Haplo-HSCT
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TCR Alpha/Beta and CD19-deplete Haplo-HSCT
Official Title: TCR Alpha/Beta and CD19-depleted Allogeneic Hematopoietic Cell Transplant for Malignant and Non-Malignant Disease
Study ID: NCT05288595
Interventions
Study Description
Brief Summary: This is an open label, interventional, non-randomized, phase II trial of TCR alpha/beta and CD19-depeleted allogeneic HCT in pediatric patients with hematologic disease.
Detailed Description: This is a single-site, open label, interventional, non-randomized, phase II trial of TCRαβ/CD19 deplete allogeneic HCT as donor source and sole GVHD prophylaxis in pediatric patients with either malignant or non-malignant hematologic disease who are eligable for allogeneic HCT, but lack a HLA-matched sibling donor.
Eligibility
Minimum Age: 31 Days
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Children's Hospital Colorado, Aurora, Colorado, United States
Contact Details
Name: Alisa B Lee Sherick
Affiliation: University of Colorado, Denver
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
